Klotho Neurosciences signs LOI to acquire Turn Biotechnologies assets

Klotho Neurosciences today announced it has signed a nonbinding Letter of Intent to acquire select assets from Turn Biotechnologies, in a transaction anchored by a $300 million global pharma deal, according to the company. Under the proposed deal, Klotho would obtain Turn’s ERA (Epigenetic Reprogramming of Age) platform and the eTurna RNA delivery system. The […] The post Klotho Neurosciences signs LOI to acquire Turn Biotechnologies assets appeared first on Longevity.Technology.